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Summary
Background.  —  Owing  to  the  heterogeneous  population  of  patients  with  acute  coronary  syn-
dromes (ACS),  risk  stratiﬁcation  with  tools  such  as  the  GRACE  risk  score  is  recommended  toAnaemia;
GRACE  score
guide therapeutic  management  and  improve  outcome.
Aim. —  To  evaluate  whether  anaemia  reﬁnes  the  value  of  the  GRACE  risk  model  to  predict
midterm outcome  after  an  ACS.
Methods.  —  A  prospective  registry  of  1064  ACS  patients  (63  ±  14  years;  73%  men;  57%  ST-segment
elevation myocardial  infarction  [MI])  was  studied.  Anaemia  was  deﬁned  as  haemoglobin  less  than
Abbreviations: ACS, acute coronary syndrome; CAD, coronary artery disease; CI, conﬁdence interval; cNRI, net reclassiﬁcation improve-
ment; ESC, European Society of Cardiology; GFR, glomerular ﬁltration rate; GRACE, Global Registry of Acute Coronary Events; HR, hazard
ratio; IDI, integrated discrimination improvement; MI, myocardial infarction.
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13  mg/dL  in  men  or  less  than  12  mg/dL  in  women.  The  primary  endpoint  was  6-month  death  or
rehospitalization  for  MI.
Results.  —  The  primary  endpoint  was  reached  in  132  patients,  including  68  deaths.  Anaemia
was associated  with  adverse  clinical  outcomes  (hazard  ratio  3.008,  95%  conﬁdence  interval
2.137—4.234;  P  <  0.0001)  in  univariate  analysis  and  remained  independently  associated  with
outcome after  adjustment  for  the  Global  Registry  of  Acute  Coronary  Events  (GRACE)  risk  score
(hazard  ratio  2.870,  95%  conﬁdence  interval  1.815—4.538;  P  <  0.0001).  Anaemia  provided  addi-
tional prognostic  information  to  the  GRACE  score  as  demonstrated  by  a  systematic  improvement
in global  model  ﬁt  and  discrimination  (c-statistic  increasing  from  0.633  [0.571;0.696]  to  0.697
[0.638;0.755]).  Subsequently,  adding  anaemia  to  the  GRACE  score  led  to  reclassiﬁcation  of  595
patients into  different  risk  categories;  16.5%  patients  at  low  risk  (≤  5%  risk  of  death  or  rehospi-
talization  for  MI)  were  upgraded  to  intermediate  (>  5—10%)  or  high  risk  (>  10%);  79.5%  patients
at intermediate  risk  were  reclassiﬁed  as  low  (55%)  or  high  risk  (24%);  and  45.5%  patients  at  high
risk were  downgraded  to  intermediate  risk.  Overall,  174  patients  were  reclassiﬁed  into  a  higher
risk category  (17.3%)  and  421  into  a  lower  risk  category  (41.9%).
Conclusion.  —  Anaemia  provides  independent  additional  prognostic  information  to  the  GRACE
score. Combining  anaemia  with  the  GRACE  score  reﬁnes  its  predictive  value,  which  often  over-
estimates  the  risk.
©  2013  Published  by  Elsevier  Masson  SAS.
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Résumé
Contexte.  —  En  raison  de  l’extrême  hétérogénéité  des  patients  hospitalisés  pour  un  syndrome
coronaire aigu,  une  stratiﬁcation  du  risque  est  recommandée  avec  des  outils  tels  que  la  score
GRACE pour  guider  la  prise  en  charge  thérapeutique  et  améliorer  le  pronostic.
Objectif.  —  Évaluer  si  l’anémie  afﬁne  la  valeur  pronostique  du  score  de  prédication  GRACE  pour
prédire les  évènements  cliniques  à  moyen  terme  après  un  syndrome  coronaire  aigu  (SCA).
Méthodes.  — Un  registre  prospectif  de  1064  patients  admis  pour  un  SCA  a  été  étudié
(63 ±  14  ans  ;  73  %  d’hommes  ;  57  %  de  SCA  ST  sus).  L’anémie  était  déﬁnie  par  un  taux
d’hémoglobine  inférieur  à  13  mg/dL  chez  les  hommes  et  inférieur  à  12  mg/dL  chez  les  femmes.
Le critère  d’évaluation  principal  était  la  survenue  de  décès  ou  ré-hospitalisation  pour  infarctus
du myocarde  à  six  mois.
Résultats.  — Le  critère  d’évaluation  était  observé  chez  132  patients  incluant  68  décès.  L’anémie
était associée  à  un  mauvais  pronostic  (HR  3,008,  CI  95  %  2,137—4,234  ;  p  <  0,0001)  en  analyse
univariée  et  restait  indépendamment  associée  au  pronostic  après  ajustement  sur  le  score  de
risque GRACE  (HR  2,870,  CI  95  %  1,815—4,538  ;  p  <  0,0001).  L’anémie  ajoutait  une  information
pronostique  additionnelle  à  celle  du  modèle  GRACE,  cela  était  démontré  par  l’amélioration
consistante  du  modèle  global  d’ajustement  et  discrimination  (augmentation  de  la  statistique
c de  0,633  [0,571  ;  0,696]  à  0,697  [0,638  ;  0,755]).  L’incorporation  de  l’anémie  dans  le  score
GRACE permettait  de  reclasser  595  patients  dans  des  catégories  différentes  de  risque  ;  16,5  %
des patients  à  bas  risque  (≤  5  %  de  décès  pour  ré-hospitalisation  pour  IDM)  étaient  reclassés
à risque  intermédiaire  (>  5—10  %)  ou  élevé  (>  10  %)  ;  79,5  %  des  patients  à  risque  intermédiaire
étaient reclassés  à  bas  risque  (55  %)  ou  risque  élevé  (24  %)  et  45,5  %  des  patients  à  risque  élevé
étaient reclassés  à  risque  intermédiaire.  Globalement,  174  patients  étaient  reclassés  à  risque
plus élevé  (17,3  %)  et  421  à  risque  moins  élevé  (41,9  %).
Conclusion.  —  L’anémie  apporte  une  information  pronostique  additionnelle  indépendante  à
celle du  score  de  risque  GRACE.  Combiner  l’anémie  au  score  GRACE  afﬁne  la  valeur  prédictive
du score  GRACE  qui  isolé  surestime  souvent  le  risque  d’évènements.
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ackground
wing  to  the  broad  and  heterogeneous  population  of
atients  with  acute  coronary  syndromes  (ACS),  early  risk
tratiﬁcation  is  highly  recommended  to  guide  therapeu-
ic  management  and  improve  outcome  (European  Society
f  Cardiology  [ESC]  guidelines)  [1].  Age,  Killip  class,  heart
ate  and  systolic  blood  pressure  have  been  identiﬁed  as
owerful  indicators  of  risk  [2,3].  When  combined  with  elec-
rocardiography,  creatinine  and  troponin  concentrations,
o
t
sn  SAS.
hese  variables  can  be  modelled  into  an  easy-to-use  score
o  further  improve  risk  stratiﬁcation.  The  Global  Reg-
stry  of  Acute  Coronary  Events  (GRACE)  risk  score  [2]
as  been  recommended  as  a  decision-making  algorithm
or  the  management  of  ACS  patients  (ESC  guidelines)
1].It  is  relevant  for  clinicians  to  know  whether  patient
utcome  can  be  improved  by  implementing  additional  easy-
o-capture  features.  Anaemia,  an  independent  correlate  of
urvival  [4],  is  present  in  up  to  43%  of  the  elderly  population
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aAnaemia  to  predict  outcome  in  patients  with  acute  coronary
presenting  with  an  ACS  but  is  not  considered  in  the  GRACE
score.
Our  aim  was  to  assess  whether  anaemia  can  improve  the
predictability  of  the  GRACE  score  in  a  prospective  cohort  of
‘real-life’  patients  hospitalized  with  an  ACS.
Methods
Study population and follow-up
Data  from  1064  consecutive  patients  with  ST-segment  ele-
vation  or  non-ST-segment  elevation  ACS  admitted  between
2009  and  2010  to  two  tertiary  care  centres  (CHRU  Lille
and  CHU  La  Pitié)  were  prospectively  collected.  ACS
was  deﬁned  using  the  ESC/American  College  of  Cardiol-
ogy  guidelines  [5,6].  Exclusion  criteria  were  mechanical
ventilation  or  initial  cardiac  arrest,  signiﬁcant  valvular
heart  disease,  bleeding  events  before  ACS  and  postopera-
tive  ACS.  Blood  samples  were  drawn  for  serum  creatinine
and  haemoglobin  concentration  determinations  on  admis-
sion.  Anaemia  was  deﬁned  according  to  the  World  Health
Organization  deﬁnition  (haemoglobin  <  13  mg/dL  in  men  or
<  12  mg/dL  in  women)  [7].  Serum  haemoglobin  concentra-
tions  were  obtained  using  a  commercially  available  device
(Beckmann  Coulter  Automated  CBC  Analyzer;  Beckman  Coul-
ter,  Inc.,  Fullerton,  CA,  USA).  The  glomerular  ﬁltration  rate
(GFR)  was  estimated  using  the  four-component  Modiﬁcation
of  Diet  in  Renal  Disease  equation  [8].  The  GRACE  risk  score
model  includes  the  following  weighted  variables:  age,  heart
rate  and  systolic  blood  pressure  on  presentation,  conges-
tive  heart  failure  Killip  class,  ST-segment  deviation,  initial
serum  creatinine  concentration,  elevated  cardiac  enzymes
and  cardiac  arrest  at  admission  [2].
The  status  of  the  patients  was  monitored  by  telephone
calls  to  referring  cardiologists  and  primary  care  physicians,
and  by  review  of  the  medical  records;  data  were  collected
as  part  of  their  routine  evaluation  at  baseline  and  at  clin-
ical  follow-up.  Informed  consent  for  access  to  protected
health  information  was  obtained.  The  registry  was  declared
to  the  Commission  Nationale  de  l’Informatique  et  des  Lib-
ertés  (CNIL).
Endpoint
The  primary  endpoint,  as  in  the  GRACE  report,  was  a
composite  of  death  and  rehospitalization  for  myocardial
infarction  (MI),  including  ST-segment  elevation  MI  or  non-
ST-segment  elevation  MI,  6  months  after  admission.
Statistical analysis
Continuous  variables  are  expressed  as  mean  ±  standard  devi-
ation  or  median  [25th;75th  percentiles],  as  appropriate.
Categorical  variables  are  presented  as  absolute  numbers
and  percentages.  Baseline  characteristics  of  subjects  with
anaemia  were  compared  with  those  of  subjects  without
anaemia  using  the  Chi-square  test  or  Fisher’s  test  for
categorical  variables  and  Student’s  t-test  for  continuous
variables.
Event-free  survival  curves  were  estimated  using  the
Kaplan-Meier  method  and  compared  using  the  log-rank  test.
Median  follow-up  time  was  estimated  with  the  reverse
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aplan-Meier  method.  Univariate  followed  by  multivariable
ox  analyses  were  performed  to  identify  independent  pre-
ictors  of  MI  or  death.  The  log-linearity  assumption  for
ontinuous  variables  and  the  proportional  hazard  assump-
ion  were  tested  by  supremum  tests.  In  case  of  violation
f  the  former  assumption,  the  continuous  variable  was
ichotomized,  the  cut-off  value  being  visually  established;
n  case  of  violation  of  the  latter  assumption,  a piece-
ise  model  was  used  to  model  the  hazard  ratio  (HR)  as  a
tep  function  of  time,  the  cut-off  value  again  being  visu-
lly  established.  Owing  to  non-proportional  hazards  for  the
RACE  score,  prognostic  factors  of  event-free  survival  were
dentiﬁed  beyond  15  days  of  admission  for  patients  who
emained  alive  and/or  without  any  new  MI  (leading  to  a
ample  of  1003  subjects).
To  assess  the  incremental  value  of  anaemia  over  the
RACE  score  on  event-free  survival  beyond  a  15-day  follow-
p  period,  improvement  in  model  performance  was  assessed
y:  Schwarz’s  Bayesian  criterion  with  the  likelihood  ratio
est  to  evaluate  the  contribution  of  anaemia  to  the  model
ombining  anaemia  with  GRACE;  change  in  Harrell’s  c-
tatistics;  change  in  Kent  and  O’Quigley’s  2;  and,  following
hambless  et  al.  [9], integrated  discrimination  improve-
ent  (IDI)  and  the  continuous  version  of  net  reclassiﬁcation
mprovement  (cNRI)  for  censored  data.  These  analyses  were
arried  out  in  the  sample  of  1003  subjects  (training  sample).
For  illustrational  purposes,  a  category-based  NRI  was
omputed,  with  a  risk  of  event  deﬁned  as  low,  intermedi-
te  and  high  for  an  estimated  cumulative  incidence  of  ≤  5%,
 5—10%  and  >  10%,  respectively.  For  each  category  of  risk
ased  on  the  GRACE  score  alone,  Kaplan-Meier  event-free
urvival  curves  were  plotted  according  to  the  reclassiﬁcation
ith  anaemia.
Internal  validity  of  the  model  including  anaemia  was  esti-
ated  by  bootstrapping  techniques.  Two  thousand  bootstrap
amples  of  1003  subjects  were  generated  and  Harrell’s  c-
tatistics,  Kent  and  O’Quigley’s  2,  the  IDI  and  the  cNRI
ere  computed  in  each  of  the  2000  samples.  For  each  per-
ormance  index,  given  numbers  are  the  mean  of  the  2000
stimates  and  95%  bootstrap  conﬁdence  intervals,  where  the
ower  and  upper  bounds  are  the  2.5%  and  97.5%  percentiles
f  the  resampling  distribution,  respectively.
A two-tailed  type  I  error  rate  less  than  0.05  was  consid-
red  for  statistical  signiﬁcance.  Analyses  were  conducted
sing  SAS  software  (SAS  version  9.1,  SAS  Institute  Inc.,  Cary,
C,  USA).
esults
tudy population
 total  of  1064  patients  with  ACS  were  included  in  the
resent  prospective  observational  registry.  Most  patients
ere  men,  54%  were  hypertensive,  24%  had  diabetes  melli-
us,  17%  had  Killip  class  greater  or  equal  to  2  and  anaemia
as  diagnosed  in  29%  of  patients  on  admission  (Table  1).
ig.  1  shows  the  distribution  of  serum  haemoglobin  at
dmission  in  the  study  population.  Fifty-seven  per  cent  had
T-segment  elevation  MI,  38%  received  glycoprotein  IIb/IIIa
nhibitors  and  12%  received  ﬁbrinolytic  therapy.  Coronary
ngiography  was  performed  in  most  patients;  primary  per-
utaneous  coronary  intervention  was  the  ﬁrst  reperfusion
360  P.V.  Ennezat  et  al.
Table  1  Baseline  characteristics  and  event  rates  of  the  study  population  according  to  anaemia.
Variable  All  No  anaemia  Anaemia  P
(n  =  1064) (n =  759)  (n  =  305)
Age  (years)  63  ±  14  60  ±  14  71  ±  13  <  0.0001
Male  sex 781  (73)  584  (77)  197  (65)  <  0.0001
History  of  CAD 277 (26) 161  (21)  116  (38)  <  0.0001
Hypertension  577  (54) 376  (50) 201  (67) <  0.0001
Diabetes  mellitus 253  (24) 149  (20) 104  (34) <  0.0001
Smoker  470  (44)  377  (50)  93  (31)  <  0.0001
ST-segment  elevation  MI  608  (57)  459  (60)  149  (49)  0.0005
Anterior  ST-segment  elevation  MI  279  (27)  224  (31)  55  (19)  <  0.0001
Killip  class  <  0.0001
1  875  (83)  658  (87)  217  (72)
2  105  (10)  59  (8)  46  (15)
3  53  (5)  23  (3)  30  (10)
4  23  (2)  13  (2)  10  (3)
Heart  rate  (bpm)  81  ±  19  80  ±  18  83  ±  20  0.04
Systolic  BP  (mmHg)  140  ±  27  141  ±  27  138  ±  28  0.25
Creatinine  (mg/dL)  0.9  [0.8;1.1]  0.9  [0.8;1.1]  1.0  [0.8;1.4]  <  0.0001
eGFR  (mL/min/1.73  m2) 83 ±  31  88  ±  29  69  ±  31  <  0.0001
Haemoglobin  (g/dL) 13  ±  2 14  ±  1  11  ±  1  <  0.0001
Anaemia  305  (29)
Peak  cardiac  troponin  I  (ng/mL) 8  [1;47] 9  [1;49]  6  [1;40]  0.004
Prior  use  of  aspirin 281  (27) 165  (22) 116  (38)  <  0.0001
Prior  use  of  clopidogrel 157  (15) 80  (11)  77  (26)  <  0.0001
Coronary  angiography 972  (92) 728  (96) 244  (80)  <  0.0001
Multivessel  CAD 196  (20) 131  (18) 65  (25) 0.01
Left  main  CAD 60 (6) 38  (5) 22 (9)  0.055
Primary  angioplasty 482  (48) 362  (50) 120  (45) 0.23
Fibrinolytic  therapy  122  (12)  101  (13)  21  (7)  0.003
Glycoprotein  IIb/IIIa  blocker  400  (38)  316  (42)  84  (28)  <  0.0001
CABG  surgery  66  (7)  46  (6)  20  (7)  0.52
Aspirin  at  discharge  1027  (98)  740  (99)  287  (96)  0.002
Clopidogrel  at  discharge  950  (91)  694  (93)  256  (86)  0.0006
GRACE  score  —  death  or  MI  25  [17;34]  23  [16;31]  32  [22;40]  <  0.0001
Events  132  (12.4)  62  (8.2)  70  (22.9)
6-month  event-free  survival  (%)  87.6  [85.5;89.4]  91.8  [89.6;93.6]  77.0  [71.9;81.4]  <  0.0001
30-day  event-free  survival  (%)  93.2  [91.6;94.6]  95.0  [93.2;96.3]  88.9  [84.8;91.9]
Data are mean ± standard deviation, median [25th;75th percentiles] or number (%). BP: blood pressure; CABG: coronary artery bypass
graft; CAD: coronary artery disease; eGFR: estimated glomerular ﬁltration rate; GRACE: Global Registry of Acute Coronary Events; MI:
myocardial infarction.
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(trategy  in  48%  and  coronary  artery  bypass  graft  surgery  was
erformed  in  7%  of  the  population.
linical and biological correlates of anaemia
n admission
lder  age,  female  sex,  history  of  coronary  artery  disease,
ypertension,  diabetes  mellitus  and  higher  Killip  class  were
ssociated  with  anaemia  on  admission  (Table  1).  Anaemia
as  more  prevalent  in  patients  without  a  history  of  smoking
nd  in  patients  with  non-ST-segment  elevation  ACS.  Heart
ate  was  slightly  higher  in  patients  with  anaemia  compared
ith  in  others.  Prior  use  of  aspirin  and  clopidogrel  was  asso-
iated  with  anaemia  on  admission,  while  ﬁbrinolytic  and
lycoprotein  IIb/IIIa  receptor  blockade  therapies  were  used
r
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iess  frequently  in  patients  with  anaemia.  Coronary  angiogra-
hy  was  performed  less  frequently  in  patients  with  anaemia
han  in  those  without  anaemia.  Patients  with  anaemia  more
requently  had  impaired  renal  function,  as  demonstrated  by
he  reduced  estimated  GFR  (Table  1).  Lastly,  patients  with
naemia  had  a  higher  GRACE  score  than  those  without.
ollow-up
here  were  132  events  during  follow-up,  including  68  deaths
Table  1).  Anaemia  was  more  frequent  in  patients  who  expe-
ienced  an  event  compared  with  in  others  (HR  3.008,  95%
onﬁdence  interval  [CI]  2.137—4.234;  P  <  0.0001).  Event-
ree  survival  according  the  presence  of  anaemia  is  presented
n  Fig.  2.  Older  age,  female  sex,  history  of  coronary
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Table  2  Univariate  Cox  models  for  the  risk  of  death  or  myocardial  infarction  in  the  study  population.
Variable  HR  95%  CI  P
Age  (per  year)  1.038  [1.025—1.052]  <  0.0001
Male  sex  0.680  [0.475—0.975]  0.04
History  of  CADa
Before  15  days  1.145  [0.628—2.086]  0.66
At  15  days  and  after  2.569  [1.655—3.987]  <  0.0001
Hypertension  1.509 [1.055—2.159] 0.02
Diabetes  1.765 [1.233—2.524] 0.002
Smoker  0.672 [0.469—0.963] 0.03
ST-segment  elevation  MIa
Before  30  days  2.254  [1.320—3.847]  0.003
At  30  days  and  after  0.501  [0.300—0.837]  0.008
Anterior  ST-segment  elevation  MI  0.918  [0.614—1.371]  0.67
Multivessel  coronary  artery  diseasea
Before  15  days  0.824  [0.385—1.762]  0.62
At  15  days  and  after  2.962  [1.794—4.891]  <  0.0001
Killip  class  ≥  2  3.684  [2.601—5.218]  <  0.0001
Heart  rate  (per  bpm)  1.010  [1.002—1.019]  0.02
Systolic  blood  pressure  (per  mmHg)a
Before  15  days  0.983  [0.973—0.994]  0.002
At  15  days  and  after  0.999  [0.991—1.008]  0.90
Creatinine  ≥  1.3  mg/dLb 3.604  [2.506—5.183]  <  0.0001
eGFR  <  60  mL/min/1.73  m2b 3.981  [2.820—5.616]  <  0.0001
Anaemia  3.008  [2.137—4.234]  <  0.0001
Peak  cardiac  troponin  I  (per  ng/mL)  1.03  [1.000—1.003]  0.02
Prior  use  of  aspirin  1.671  [1.1-9—2.387]  0.005
Prior  use  of  clopidogrel  1.600  [1.053—2.432]  0.03
Coronary  angiographya
Before  30  days  0.714  [0.342—1.489]  0.37
At  30  days  and  after  0.176  [0.103—0.303]  <  0.0001
Main  left  coronary  artery  disease  1.439  [0.727—2.846]  0.30
Fibrinolytic  therapy  0.778  [0.429—1.408]  0.41
Glycoprotein  IIb/IIIa  receptor  blocker  0.628  [0.429—0.919]  0.02
CABG  surgery  0.753  [0.331—1.711]  0.50
Aspirin  at  discharge 0.283  [0.125—0.643]  0.003
Clopidogrel  at  discharge  0.586  [0.351—0.978]  0.04
GRACE  score  —  death  or  MI  (per  %)a
Before  15  days 1.060 [1.047—1.073]  <  0.0001
At  15  days  and  after  1.036  [1.022—1.049]  <  0.0001
CABG: coronary artery bypass graft; CAD: coronary artery disease; CI: conﬁdence interval; eGFR: estimated glomerular ﬁltration rate;
GRACE: Global Registry of Acute Coronary Events; HR: hazard ratio; MI: myocardial infarction.
a Proportional hazard assumption not met.
b Log-linearity assumption not met.
Table  3  Multivariable  Cox  model,  not  including  the  GRACE  risk  score,  for  the  risk  of  death  or  myocardial  infarction  at
6  months  in  the  study  population.
Variables  HR  95%  CI  P
Multivessel  CAD  2.414  [1.445—4.032]  0.0008
eGFR  <  60  mL/min/1.73  m2 2.354  [1.363—4.063]  0.002
Anaemia  on  admission  2.262  [1.331—3.843]  0.003
CAD: coronary artery disease; CI: conﬁdence interval; eGFR: estimated glomerular ﬁltration rate; GRACE: Global Registry of Acute
Coronary Events; HR: hazard ratio.
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Table  4  Predictive  performance  (calibration,  discrimination  and  reclassiﬁcation)  for  6-month  mortality  or  myocardial
infarction  of  the  GRACE  score  (model  1)  and  the  composite  of  GRACE  score  +  anaemia  (model  2).
  HR  95%  CI  P
Model  1:  GRACE  score
GRACE  score  —  death  or  MI  (per  %) 0.03  1.036  [1.022—1.049]  <  0.0001
Model  2:  GRACE  score  +  anaemia
Anaemia  1.1  2.870 [1.815—4.538] <  0.0001
GRACE  score  —  death  or  MI  (per  %)  0.03  1.027  [1.013—1.042]  0.0003
Model  1:  GRACE  score  Model  2:  GRACE  score  +  anaemia
Global  ﬁt
—2LL  1077  1056
SBC  1081  1065
Discrimination
Harrell’s  c-statistics  0.633  [0.571;0.696]  0.697  [0.638;0.755]
Calibration
Kent  and  O’Quigley’s  2 0.139  0.254
Reclassiﬁcation
cNRI  (%)  62.2
Among  event  subjects 12.5
Among  non-event  subjects 49.7
IDI  (%) 2.3
—2LL: —2 likelihood; CI: conﬁdence interval; cNRI: continuous net reclassiﬁcation improvement; GRACE: Global Registry of Acute
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experience  an  event  being  reclassiﬁed.  Reclassiﬁcation  was
achieved  in  49.7%  of  patients  who  did  not  experience  anCoronary Events; HR: hazard ratio; IDI: integrated discriminatio
criterion.
rtery  disease  (CAD),  diabetes  mellitus,  ST-segment  ele-
ation  MI,  Killip  class  ≥  2,  increased  heart  rate  and  low
lood  pressure  were  also  associated  with  the  risk  of  death
uring  follow-up.  Impaired  renal  function  and  higher  peak
ardiac  troponin  I  were  associated  with  poor  outcome
Table  2).  Lack  of  use  of  coronary  angiography  or  prior  use
f  antiplatelet  therapy  was  also  associated  with  poorer  out-
ome.  As  expected,  a  higher  GRACE  score  predicted  poor
utcome  (beyond  2  weeks  of  follow-up:  HR  1.036,  95%  CI
.022—1.049;  P  <  0.0001).  No  interaction  was  found  between
naemia  and  age  for  predicting  outcome  (P  for  interac-
ion  =  0.62);  hence,  no  further  subgroup  analysis  based  on
ge  was  carried  out.  By  multivariable  Cox  analysis  with-
ut  including  the  GRACE  risk  score  (Table  3),  multivessel
AD,  impaired  renal  function  and  anaemia  were  found  to
e  independently  associated  with  outcome.  Table  4  shows
igure 1. Graph showing the distribution of serum haemoglobin
t admission in the study population.
e
e
F
aprovement; MI: myocardial infarction; SBC: Schwarz’s Bayesian
hat  the  combined  model  of  anaemia  plus  the  GRACE  score
ad  a  better  predictive  value  than  the  GRACE  score  alone,
s  demonstrated  by  better  global  ﬁt  and  calibration.  In
ddition,  improvements  in  discrimination  by  model  2 were
onﬁrmed  by  the  IDI  at  2.3%,  suggesting  a  further  average
eparation  of  events  from  non-events  of  2.3%  (Table  4).
Addition  of  anaemia  to  the  GRACE  score  model  led  to  a
igniﬁcant  net  reclassiﬁcation  of  patients  in  the  appropriate
irections.  Accordingly,  the  continuous  category-free  NRI
as  high  at  62.2%,  with  the  contribution  of  12.5%  patients
ho  experienced  an  event  and  49.7%  patients  who  did  notvent  but  in  only  12.5%  of  patients  who  experienced  an
vent.
igure 2. Kaplan-Meier curve representing event-free survival
ccording to the presence of anaemia. MI: myocardial infarction.
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Figure 3. Proportion of patients reclassiﬁed into different risk
categories when adding anaemia to the Global Registry of Acute
Figure 4. Cumulative incidence of events in reclassiﬁed patients
according to the composite model of Global Registry of Acute
Coronary Events (GRACE) score + anaemia in: (A) low-risk patients
according to the GRACE score (≤ 5% risk); (B) intermediate-risk
patients according to the GRACE score (> 5—10% risk); (C) high-
r
i
DCoronary Events (GRACE) score, according to risk categories pre-
dicted by the GRACE score alone.
Potential  for  clinical  beneﬁt  achieved  when  anaemia
was  combined  with  the  GRACE  score  was  assessed  using
the  category-based  NRI.  Reclassiﬁcations  are  summarized
in  Table  5.  As  depicted  in  the  Methods  section,  we  used
5%  and  10%  as  thresholds  (overall  event  rate  13%)  to  deﬁne
patients  as  being  at  low,  intermediate  and  high  risk  accord-
ing  to  the  GRACE  score.  Hence,  as  depicted  in  Fig.  3,
of  206  patients  categorized  as  low  risk  by  the  GRACE
score,  34  were  reclassiﬁed  into  different  categories  (16.5%),
27  being  reclassiﬁed  as  intermediate  risk  (observed  event
rate  7.4%)  and  seven  as  high  risk  (observed  event  rate
28.6%).  Of  the  584  patients  categorized  as  intermediate
risk  by  the  GRACE  score,  464  were  reclassiﬁed  into  differ-
ent  categories  (79.5%),  324  being  reclassiﬁed  as  low  risk
(observed  event  rate  4%)  and  140  as  high  risk  (observed
event  rate  14.3%).  Of  the  213  patients  categorized  as  high
risk  by  the  GRACE  score,  97  (45.5%)  were  downgraded
into  intermediate  risk  (observed  event  rate  8.2%).  Overall,
174  patients  were  reclassiﬁed  into  a  higher  risk  category
(17.3%)  and  421  into  a  lower  risk  category  (41.9%).  As  for
the  continuous  NRI,  the  category-based  NRI  of  30.8%  was
mainly  determined  by  27.1%  of  patients  who  did  not  experi-
ence  an  event  and  only  3.7%  of  patients  who  experienced
an  event.  In  other  words,  the  composite  score  based  on
GRACE  score  +  anaemia  had  a  better  predictive  value  in  non-
event  patients,  underlying  the  overestimation  of  risk  by
the  GRACE  score  alone.  Fig.  4A—C  shows  survival  curves  of
patients  reclassiﬁed  by  the  composite  of  GRACE  score  plus
anaemia  according  to  their  original  category  of  GRACE  risk
score.Internal  validity  of  the  combined  model  over  the  GRACE
score  alone  was  ultimately  validated  by  bootstrapping  tech-
niques,  with  ﬁndings  similar  to  those  obtained  with  previous
analysis  (Table  6).
O
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6isk patients according to GRACE score (> 10% risk). MI: myocardial
nfarction.
iscussion
ur  data  demonstrate  that  in  a  prospective  cohort  of
onsecutive  patients  hospitalized  for  an  ACS,  anaemia  is
ssociated  with  a  three-fold  increased  risk  of  death  or  MI  at
-month  follow-up.  Anaemia  provided  additional  prognostic
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Table  5  Reclassiﬁcation  across  predeﬁned  risk  thresholds  using  the  composite  of  GRACE  score  +  anaemia.
GRACE  score  +  anaemia
≤  5%  5—10%  >  10%  Total
GRACE  score  alone
≤  5% 172  (3.5) 27  (7.4) 7  (28.6) 206  (4.9)
>  5—10%  324  (4.0)  120  (5.0)  140  (14.3)  584  (6.7)
>  10%  0  97  (8.2)  116  (19.8)  213  (14.6)
Total  496  (3.8)  244  (6.6)  263  (17.1)  1003  (8.0)
Data are number (%). GRACE: Global Registry of Acute Coronary Events.
Category-based net reclassiﬁcation improvement, 30.8%; among event subjects, 3.7%; among non-event subjects, 27.1%.
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wnformation  over  the  GRACE  score.  Importantly,  the  addition
f  anaemia  to  the  GRACE  score  allows  for  reclassiﬁcation
f  an  important  proportion  of  the  study  population  into  a
ower  risk  category  (421  patients;  42%).  Besides  creatinine
nd  cardiac  troponin,  haemoglobin  may  deserve  to  be  rou-
inely  incorporated  into  the  risk  stratiﬁcation  of  patients
ith  an  ACS,  to  improve  risk  stratiﬁcation  and  long-term
vent  prediction.  Haemoglobin  concentration  is  a  power-
ul  predictive  factor  for  mortality  and  morbidity  in  patients
ith  ACS  [10—12]  but  also  with  various  other  illnesses,
ncluding  heart  failure  [13],  kidney  dysfunction  [14]  and
he  whole  spectrum  of  CAD  [15,16].  Anaemia,  present  in
ne-third  of  ACS  patients  in  agreement  with  previous  stud-
es  [17,18],  predicted  a  worse  prognosis.  Anaemia  not  only
ecreases  oxygen  delivery  to  the  injured  myocardium  and
eriphery,  associated  with  the  risk  of  increased  infarct  size,
rrhythmias  and  hypotension,  but  is  also  an  integrator  of
omorbid  conditions,  such  as  older  age,  diabetes  and  kidney
ysfunction.  Therapies  aimed  at  correcting  anaemia,  the
aemoglobin  value  threshold  at  which  to  treat  and  the  tar-
et  haemoglobin  value  still  remain  sources  of  investigation
nd  debate.
The  comprehensive  GRACE  score  combines  factors  that
ere  found  to  be  associated  independently  with  increased
ortality,  including  age,  heart  rate,  systolic  blood  pres-ure,  ST-segment  deviation,  serum  creatinine  and  cardiac
roponin,  cardiac  arrest  at  presentation  and  Killip  class.
eneveau  et  al.  [18]  reported  previously  that  anaemia  on
dmission  provided  independent  prognostic  information  on
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Table  6  Internal  validity  by  bootstrapping.
Model  1:  GRACE  score  
Discrimination
Harrell’s  c-statistics  0.633  [0.564;0.697]  
Calibration
Kent  and  O’Quigley’s  2 0.138  [0.057;0.219]  
Reclassiﬁcation
cNRI  (%)  62.0  [39.3;84.4]
Among  event  subjects  12.3  [−9.8;34.2]
Among  non-event  subjects  49.7  [44.3;55.0]
IDI  (%)  2.4  [0.6;5.0]
cNRI; continuous net reclassiﬁcation improvement; GRACE: Global Re
improvement.op  of  the  GRACE  score  for  the  prediction  of  mortality  or  MI
n  ACS  patients  at  1-month  follow-up.  In  contrast,  we  looked
t  6-month  clinical  outcome,  as  in  the  GRACE  score  sys-
em.  This  study,  like  that  of  Meneveau  et  al.,  demonstrates
learly  the  clinical  signiﬁcance  of  combining  anaemia  with
he  GRACE  score  for  predicting  outcome  in  ACS  patients.
ence,  risk  estimate  using  the  GRACE  score  alone  was  inap-
ropriate  in  an  important  proportion  of  ACS  patients.  Adding
naemia  to  the  GRACE  score  led  to  a  substantial  reclassiﬁ-
ation  of  ACS  patients  into  a  lower  risk  category  (42%  of  the
tudy  cohort).  The  accuracy  of  the  combined  model  for  pre-
icting  clinical  outcome  was  much  better  than  that  of  the
RACE  score  alone.
tudy limitations
his  study,  which  included  a  relatively  small  number  of
CS  patients,  may  represent  an  initial  proof  of  concept
n  the  evaluation  process  of  a  novel  marker  of  cardiovas-
ular  disease  risk  [19];  another  larger  prospective  cohort
s  needed  to  give  external  validity  to  the  present  results.
owever,  the  robust  statistical  approach  with  bootstrap
echniques  demonstrates  that  a  systematic  improvement  in
odel  ﬁt,  calibration  and  discrimination  may  be  expected
hen  combining  anaemia  with  the  GRACE  score.  The  clin-cal  signiﬁcance  of  this  improvement  is  clearly  illustrated
y  divergent  survival  curves  among  reclassiﬁed  patients
ith  different  risk  categories.  Bleeding  events  [20,21]  and
ransfusion  [22],  both  of  which  have  been  shown  to  affect
Model  2:  GRACE  score  +  anaemia  Difference
0.696  [0.634;0.756]  0.064  [0.019;0.114]
0.256  [0.151;0.358]  0.118  [0.044;0.204]
gistry of Acute Coronary Events; IDI; integrated discrimination
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outcome,  were  not  speciﬁcally  studied.  Lastly,  the  cause
of  the  anaemia  (occult  bleeding,  chronic  kidney  dysfunc-
tion,  malignancy,  inﬂammation,  thyroid  dysfunction,  etc.)
was  not  thoroughly  investigated.
Conclusion
Anaemia  on  admission  is  a  strong  independent  risk  of  poor
6-month  outcome  in  ACS  patients.  Adding  anaemia  appears
to  reﬁne  the  GRACE  score,  which  often  overestimates  the
risk.  Our  study,  combined  with  others,  strongly  suggests  that
anaemia  should  be  integrated  into  the  risk  stratiﬁcation
beyond  the  GRACE  score  in  ACS  patients.  Further  validation
in  large  prospective  multicentre  registries  is  needed  to  jus-
tify  the  inclusion  of  anaemia  in  a  better-performing  modiﬁed
GRACE  score.
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